November 5
Transcription
November 5
Organized by: Support: Official Travel Agency: blumar.com.br Official Travel Agency: COMUNICAÇÃO SCIENTIFIC PROGRAM November 5th November 6th MAIN AUDITORIUM 08:40 – 08:50 Opening remarks 08:50 - 10:30 08:50 - 09:10 09:10 - 09:30 09:30 - 09:50 09:50 - 10:10 PLENARY SESSION - Closing the quality gap Improving the process of care Can Surviving Sepsis Campaign bundles help? Is Brazil a resource limited country? Expensive new treatments and diagnostics: how can we afford them? 10:10 - 10:30 Discussion ROOM 01 CHAIRS: Tom van der Poll (ISF) Reinaldo Salomão(ILAS) José Mario Teles (AMIB) Derek Angus Philip Dellinger Flavia Machado TBD 10:30 - 11:00 COFFEE 11:00 - 12:40 11:00 - 11:20 11:20 - 11:40 11:40 - 12:00 12:00 - 12:20 12:20 - 12:40 PLENARY SESSION - The great fluid dilemmas Considerations What should we give – (i) colloid or crystalloid? What should we give - (ii) balanced or unbalanced? What amount is safe? Where next? Can recommendations be made? Group discussion Jean-Louis Vincent Konrad Reinhart Luciano Azevedo Gordon Bernard ALL 08:30 - 10:10 THEMATIC SESSION - Contemporary topics in clinical management - Part II 08:30 - 08:50 Sepsis coagulopathy: when to treat and when to watch 08:50 - 09:10 Antibiotic stewardship – why, how, when and to whom? 09:10 - 09:30 End-of-life ICU care – an international consensus 09:30 - 09:50 New devices for sepsis 09:50 - 10:10 Immunonutrition: should we bother? 10:10 - 11:00 COFFEE 11:00 - 12:30 PRO/CON - Killing the bug We must use biomarkers to guide antibiotic duration 11:00 - 11:45 Pro: Con: It is time to stop combined antibiotic therapy for severe sepsis 11:45 - 12:30 Pro: Con: 12:30 - 14:00 TBD Steven Opal Charles Sprung Phillip Dellinger Flavia Machado Jean-Paul Mira Jorge Salluh Thiago Lisboa Thierry Calandra LUNCH + SATELLITE SYMPOSIUM 12:40 - 14:00 LUNCH + SATELLITE SYMPOSIUM ROOM 01 ROOM 02 14:00 – 15:40 THEMATIC SESSION - Contemporary topics in clinical management 14:00 – 14:20 Managing and preventing cerebral dysfunction 14:20 – 14:40 Respiratory end points of resuscitation 14:40 – 15:00 When to start renal replacement therapy 15:00 – 15:20 Hemodynamic end points of resuscitation 15:20 - 15:40 Managing and preventing ICU acquired weakness 08:30 - 10:10 08:30 - 08:50 08:50 - 09:10 09:10 - 09:30 09:30 - 09:50 09:50 - 10:10 10:10 - 11:00 Fernando Bozza Gordon Bernard Jean-Paul Mira Glenn Hernandez Felipe Dal Pizzol 15:40 - 16:30 COFFEE 11:00 - 11:45 Pro: Con: A target mean BP of 65 mmHg is unnecessarily high 11:45 - 12:30 Pro: Con: ROOM 02 THEMATIC SESSION - Beyond the typical sepsis bug Preparing for the next pandemic Interactions between HIV & sepsis Meliodosis, TB and other nasties Interactions between malaria & sepsis Emerging diseases in a shrinking world John Marshall Andre Japiassu Tom van der Poll Hugo Castro Faria Neto Thierry Calandra 15:40 - 16:30 COFFEE 16:30 – 17:00 ORAL PRESENTATIONS – Epidemiology research ROOM 03 14:00 – 15:40 14:00 – 14:20 14:20 – 14:40 14:40 – 15:00 15:00 – 15:20 15:20 - 15:40 THEMATIC SESSION - Better models of sepsis In vitro models Of mice, rats and men Large animal models: the best choice In silico models Human volunteers John Marshall Jean-Paul Mira Derek Angus Alexandre Biasi Gordon Bernard 11:00 - 12:30 PRO/CON - Challenging the guidelines It is unsafe to resuscitate without SvO2 16:30 – 17:00 ORAL PRESENTATIONS – Clinical research 14:00 – 15:40 14:00 – 14:20 14:20 – 14:40 14:40 – 15:00 15:00 – 15:20 15:20 - 15:40 THEMATIC SESSION - Fixing sepsis trials Designing smarter phase II trials Theragnostics are the way ahead Should we use adaptive designs? Getting away from mortality as an endpoint Big is beautiful COFFEE 08:30 - 10:10 08:30 - 08:50 08:50 - 09:10 09:10 - 09:30 09:30 - 09:50 09:50 - 10:10 THEMATIC SESSION - New translations from the lab The role of heme Target the neutrophil Target metabolic-energetic stress Sepsis: immune exhaustion or immune reprogramming? New drug development from the biotech/ industry perspective 10:10 - 11:00 COFFEE 15:40 - 16:30 COFFEE 16:30 – 17:00 ORAL PRESENTATIONS – Basic research 12:30 - 14:00 POSTER VIEWING - 17:30 - 19H00 All sections with simultaneous translations Charles Sprung Eliezer Silva ROOM 03 11:00 - 12:30 PRO/CON - Back from the grave? We should ban catecholamines 11:00 - 11:45 Pro: Con: We need to develop anti-inflammatory therapies 11:45 - 12:30 Pro: Con: Hugo Castro Faria Neto Mervyn Singer Luciano Azevedo Mitchell Fink Tom van der Poll Phillip Dellinger Konrad Reinhart Marcelo Bozza Fernando Cunha Mervyn Singer Reinaldo Salomão Mitchell Fink Mervyn Singer Jean-Louis Vincent Steven Opal Fernando Bozza LUNCH + SATELLITE SYMPOSIUM MAIN AUDITORIUM 14:00 – 15:40 PLENARY SESSION - Early detection and Identification of the bug 14:00 – 14:20 Understanding PoC technologies 14:20 – 14:40 Pathogen detection 14:40 – 15:00 Host response detection 15:00 – 15:20 Early markers of organ dysfunction 15:20 - 15:40 Discussion Steven Opal Thierry Calandra Tom van der Poll Jean-Louis Vincent 15:40 - 16:10 COFFEE Online registration www.forumsepse.com.br 16:10 – 17:00 16:10 - 16:25 16:25 - 16:40 16:40 - 16:55 16:55 - 17:10 17:10 - 17:25 17:25 - 17:50 PLENARY SESSION: UPDATE ON CLINICAL TRIALS The early goal directed therapy trials Ongoing Canadian trials Ongoing European trials Ongoing Industry trials Ongoing Brazilian trials The new ARDSnet trial group – PETAL Derek Angus John Marshall Jean-Paul Mira Steven Opal Marcio Soares Gordon Bernard E EVENTOS
Similar documents
Sepsis-Specific Treatment Market Will Expand from 2016 and Reach $354 Million by 2021
Following the first sepsis-specific product launch in 2016, the treatment market will expand at a Compound Annual Growth Rate (CAGR) of 69% to reach $354 million by 2021 across the six major markets (6MM) of the US, UK, France, Germany, Italy and Spain, according to research and consulting.
More information